Peter F.
- Country
- Austria
- Department
- Department of Internal Medicine, Division of Gastroenterology and Hepatology, Auenbruggerplatz 15
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Study of Oral Elafibranor 120 mg in Adults with Primary Sclerosing Cholangitis
- Phase III Double-Blind, Randomized, Placebo-Controlled Study of Norursodeoxycholic Acid in Primary Sclerosing Cholangitis Patients
- Evaluation of Norucholic Acid in the Treatment of Primary Sclerosing Cholangitis: An Open-Label Study
Data & Insights
Has run more than one trial at 20 of 92 partner sites.
Specializations
Hepatobiliary Medicine
The investigator specializes in the treatment of primary sclerosing cholangitis (PSC), a chronic liver disease affecting the bile ducts. Their research focuses on innovative therapeutic approaches for managing this challenging condition.
- Chronic liver diseases
- Bile duct disorders
- Progressive biliary conditions
Their expertise extends to evaluating novel therapeutic compounds for bile duct disorders.
Clinical Therapeutics
The investigator conducts research into new therapeutic agents for cholangitic diseases, with particular attention to safety and efficacy evaluation of experimental treatments.
- Novel therapeutic compounds
- Disease progression markers
- Treatment safety assessment
Their work encompasses both open-label and controlled clinical studies of emerging treatments.
Gastroenterology
Research activities center on advanced hepatobiliary disorders and their treatment modalities, with emphasis on progressive autoimmune conditions affecting the digestive system.
- Hepatobiliary diseases
- Autoimmune disorders
- Digestive system conditions
The investigator's work contributes to advancing treatment options for complex gastrointestinal disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.